Apotex Leans Into Brand Ambitions With Formosa Deal
Acquires Canadian Rights To Novel Clobetasol Propionate Ophthalmic Treatment
Executive Summary
Apotex has made another move to bolster its burgeoning branded business, striking a deal with Formosa Pharmaceuticals for Canadian rights to its novel clobetasol propionate ophthalmic suspension.